JP2017512204A - うつ病および大うつ病性障害を治療するための方法 - Google Patents

うつ病および大うつ病性障害を治療するための方法 Download PDF

Info

Publication number
JP2017512204A
JP2017512204A JP2016554883A JP2016554883A JP2017512204A JP 2017512204 A JP2017512204 A JP 2017512204A JP 2016554883 A JP2016554883 A JP 2016554883A JP 2016554883 A JP2016554883 A JP 2016554883A JP 2017512204 A JP2017512204 A JP 2017512204A
Authority
JP
Japan
Prior art keywords
variant
cacna1c
csmd1
primers
zscan4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016554883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512204A5 (enExample
Inventor
エリック ライ
エリック ライ
ジャーラス フレンチ‐ミューレン
ジャーラス フレンチ‐ミューレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2017512204A publication Critical patent/JP2017512204A/ja
Publication of JP2017512204A5 publication Critical patent/JP2017512204A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016554883A 2014-03-05 2015-03-04 うつ病および大うつ病性障害を治療するための方法 Pending JP2017512204A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461948529P 2014-03-05 2014-03-05
US61/948,529 2014-03-05
US201462061417P 2014-10-08 2014-10-08
US62/061,417 2014-10-08
PCT/US2015/018701 WO2015134585A1 (en) 2014-03-05 2015-03-04 Method for treating depression and major depressive disorder

Publications (2)

Publication Number Publication Date
JP2017512204A true JP2017512204A (ja) 2017-05-18
JP2017512204A5 JP2017512204A5 (enExample) 2018-04-12

Family

ID=54055831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554883A Pending JP2017512204A (ja) 2014-03-05 2015-03-04 うつ病および大うつ病性障害を治療するための方法

Country Status (12)

Country Link
US (1) US20170137880A1 (enExample)
EP (1) EP3114239A4 (enExample)
JP (1) JP2017512204A (enExample)
KR (1) KR20160127126A (enExample)
CN (1) CN106536751A (enExample)
AU (1) AU2015227296A1 (enExample)
CA (1) CA2940683A1 (enExample)
IL (1) IL247379A0 (enExample)
MA (1) MA39485A (enExample)
MX (1) MX2016011384A (enExample)
RU (1) RU2016138574A (enExample)
WO (1) WO2015134585A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
PL3528811T3 (pl) * 2017-03-30 2022-01-10 Rundle Research, LLC Wortioksetyna i inhibitory mao do leczenia depresji
EP3909600A1 (en) * 2020-05-12 2021-11-17 International Centre For Genetic Engineering And Biotechnology - ICGEB Emid2 protein as anti-cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541216A (ja) * 2006-06-16 2009-11-26 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン
WO2012109562A2 (en) * 2011-02-10 2012-08-16 Baker Hughes Incorporated Flow control device and methods for using same
WO2013074676A2 (en) * 2011-11-14 2013-05-23 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2581454B1 (en) * 2008-01-17 2015-09-16 Suregene LLC Genetic markers of mental illness
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2622101A4 (en) * 2010-10-01 2014-04-02 Rigshospitalet Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
WO2012109565A1 (en) * 2011-02-10 2012-08-16 Neurotherics, Llc Genetic identification of response to antidepressant medications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541216A (ja) * 2006-06-16 2009-11-26 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン
WO2012109562A2 (en) * 2011-02-10 2012-08-16 Baker Hughes Incorporated Flow control device and methods for using same
WO2013074676A2 (en) * 2011-11-14 2013-05-23 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRANSL PSYCHIATRY, 2012, VOL.2, P.E129, JPN6018050436, ISSN: 0003944138 *

Also Published As

Publication number Publication date
EP3114239A1 (en) 2017-01-11
KR20160127126A (ko) 2016-11-02
RU2016138574A (ru) 2018-04-06
CN106536751A (zh) 2017-03-22
WO2015134585A1 (en) 2015-09-11
MX2016011384A (es) 2017-05-01
CA2940683A1 (en) 2015-09-11
US20170137880A1 (en) 2017-05-18
RU2016138574A3 (enExample) 2018-10-12
IL247379A0 (en) 2016-11-30
AU2015227296A1 (en) 2016-09-08
MA39485A (fr) 2015-09-11
EP3114239A4 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
US20090191568A1 (en) Methods and compositions for predicting compliance with an antidepressant treatment regimen
KR101784164B1 (ko) 돼지의 포화 및 불포화 지방산 함량을 조절하는 snp 및 이의 용도
US12065702B2 (en) Mitochondrial markers of neurodegenerative diseases
KR20170056136A (ko) 돈육내 다가 불포화지방산 함량 조절용 snp 마커 및 그의 용도
KR20140087044A (ko) 유기체 검출을 위한 방법 및 시스템
US20160032369A1 (en) Method and kit for genetic analysis
WO2009036514A2 (en) Method of amplifying nucleic acid
JP2017512204A (ja) うつ病および大うつ病性障害を治療するための方法
CN104293968B (zh) 一组用于检测非综合征性唇腭裂遗传易感性的多态性位点及检测试剂盒
CN104937113B (zh) 用于预测由基于抗精神病药物的治疗诱导的锥体外系症状(eps)的发病的方法
JP2007526764A (ja) アルツハイマー病の発症年齢に関連するａｐｏｅ遺伝子マーカー
JP6904676B2 (ja) カロリー制限およびカロリー制限模倣物の同定用マーカー
US20150167087A1 (en) Biomarkers for post-traumatic stress states
CN115515680A (zh) 用于评估神经递质转运蛋白抑制剂的功效的组合物和方法
WO2017087735A1 (en) Method for treating crohn's disease
US20190078161A1 (en) Method for identifying clinical trial responders from a placebo group in major depression
US20050255498A1 (en) APOC1 genetic markers associated with age of onset of Alzheimer's Disease
JP2007510404A (ja) アルツハイマー病の発症年齢に関連するｎｔｒｋ１遺伝子マーカー
TW201625799A (zh) 治療憂鬱症和重度憂鬱症之方法
KR101823376B1 (ko) 돈육내 스테아릭산 함량 조절용 snp 마커 및 그의 용도
WO2016123543A1 (en) Method for treating schizophrenia comprising administering lurasidone
CN105803052A (zh) 检测乙醇耐受基因的方法和试剂盒
KR101821541B1 (ko) 돈육내 팔미톨레인산 함량 조절용 snp 마커 및 그의 용도
Orrù et al. Clinical Practice & Epidemiology in Mental Health
Borrageiro Investigation of differential gene expression in Parkinson's disease patients: A whole transcriptome approach

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190702